Estimación de la Relación Costo-Efectividad de las Vacunas Neumocócicas Conjugadas Prevenar-13 y Synflorix®, Utilizadas en Los Programas de Vacunación de Población Infantil Mexicana
| Autor: | Maria Yolanda Cervantes-Apolinar, Jorge A. Gómez, Alberto Villaseñor-Sierra, Gerardo Martinez Aguilar, Roberto Carreño Manjarrez |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Gerontology
Heptavalent Pneumococcal Conjugate Vaccine Cost effectiveness Cost-Benefit Analysis Economics Econometrics and Finance (miscellaneous) Health outcomes Pneumococcal Infections Pneumococcal Vaccines 03 medical and health sciences 0302 clinical medicine Conjugated vaccines Humans Medicine 030212 general & internal medicine Mexico Pharmacology Toxicology and Pharmaceutics (miscellaneous) health care economics and organizations Vaccines Conjugate 030505 public health business.industry Health Policy Vaccination Infant Streptococcus pneumoniae Vaccination Campaigns Life years gained Lower cost Quality-Adjusted Life Years 0305 other medical science business Demography Pediatric population |
| Zdroj: | Value in Health Regional Issues. 11:76-84 |
| ISSN: | 2212-1099 |
| DOI: | 10.1016/j.vhri.2016.07.009 |
| Popis: | Objective To estimate the cost effectiveness associated with the use of pneumococcal conjugated vaccines, Prevenar-13 and Synflorix® , in the Mexican pediatric population. Methods The cost-effectiveness ratio of instrumenting vaccination programs based upon the use of Prevenar-13 and Synflorix® in the Mexican pediatric population was estimated by using a Markov's simulation model. The robustness of the conclusions reached on cost-effectiveness for both vaccines was assayed through an univariate and probabilistic sensitivity analysis that included all of the parameters considered by the model. Results Synflorix ® was dominant over Prevenar-13 in the cost-utility analysis; the former generated more quality-adjusted life years at a lower cost and with a lower incremental cost-utility ratio. Based on the cost-effective analysis, Prevenar-13 generated more life years gained but at a higher cost. The use of Prevenar-13 originated a higher incremental cost-effectiveness ratio and, therefore, it was not cost-effective as compared with Synflorix ®. Conclusions Even though the simulations for Prevenar-13 and Synflorix® revealed both of them to be cost-effective when used to instrument pediatric vaccination campaigns in Mexico, Synflorix® had a better cost-utility/effectiveness profile. In addition, although Prevenar-13 and Synflorix® produced equivalent health outcomes, the overall analysis predicted that Synflorix® would save 360 million Mexican pesos, as compared with Prevenar-13 . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect